Dolby Laboratories Inc (DLB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Dolby Laboratories Inc (DLB) reports a 13% revenue increase, fueled by robust licensing performance and expanding automotive partnerships.
Compared to Estimates, Dolby Laboratories (DLB) Q1 Earnings: A Look at Key Metrics
Dolby Laboratories (DLB) reported $357 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 13.1%. EPS of $1.14 for the same period compares to $1.01 a year ago.
Dolby Laboratories, Inc. (NYSE:DLB) Q1 2025 Earnings Call Transcript
Q1 2025 Earnings Call Transcript January 29, 2025 Dolby Laboratories, Inc. beats earnings expectations. Reported EPS is $1.14, expectations were $1.07. Operator: Ladies and gentlemen, thank you for standing by.
Dolby's Q1 Earnings & Revenues Surpass Estimates, Increase Y/Y
DLB's fiscal first-quarter 2025 performance gains from steady growth in the Licensing, and the Products and services segments.
Dolby Laboratories Earnings Review: Q1 Summary
Dolby Laboratories beat estimated earnings by 16.0%, reporting an EPS of $1.14 versus an estimate of $0.98. Revenue was up $41.42 million from the same period last year. In the previous quarter, the company beat on EPS by $0.11, resulting in a 16.0% increase change in the share price the following day.
Barrington Reaffirms Their Buy Rating on Dolby Laboratories (DLB)
Barrington analyst Patrick Sholl maintained a Buy rating on Dolby Laboratories (DLB – Research Report) today and set a price target of $100.00.
Here's Why We Think Dolby Laboratories (NYSE:DLB) Is Well Worth Watching
The trick, as an investor, is to find companies that are going to perform well in the future, not just in the past. While crystal balls don't exist, you can check our visualization of consensus analyst forecasts for Dolby Laboratories' future EPS 100% free.
Dolby Laboratories (DLB) Tops Q1 Earnings and Revenue Estimates
Dolby Laboratories (DLB) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $1.01 per share a year ago. These figures are adjusted for non-recurring items.
Rosenblatt Securities Sticks to Their Buy Rating for Dolby Laboratories (DLB)
In a report released yesterday, Steve Frankel from Rosenblatt Securities reiterated a Buy rating on Dolby Laboratories (DLB – Research Report),
Dolby Laboratories Inc (DLB) Q1 2025 Earnings Report Preview: What To Expect
Dolby Laboratories Inc (NYSE:DLB) is set to release its Q1 2025 earnings on Jan 29, 2025. The consensus estimate for Q1 2025 revenue is $346.15 million, and the earnings are expected to come in at $0.
CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference
Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from ...
news.stocktradersdaily6d
How the (DLB) price action is used to our Advantage
Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.
stocknews13d
Is Dolby Laboratories a Sound Investment in Audio Technology?
Audio technology is evolving at a rapid pace with growing investments in cutting-edge technologies and innovations. Dolby ...
CervoMed provides update on neflamapimod DLB program
CervoMed (CRVO) provided an update on its neflamapimod development program in dementia with Lewy bodies, DLB, as part of an oral presentation ...
Knowridge5d
This test could achieve early diagnosis of dementia with Lewy bodies
A new study published in Alzheimer’s & Dementia highlights a significant step forward in diagnosing Dementia with Lewy Bodies ...